EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Follow‐Up and Comparative Assessment of SARS‐CoV‐2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA‐1273 Heterologous Booster Vaccination

Salma Younes, Eleonora Nicolai, Massimo Pieri, Sergio Bernardini, Hanin I Daas, Duaa W Al-Sadeq, Nadin Younes, Farah M Shurrab, Parveen B Nizamuddin, Fathima Humaira, Nader Al-Dewik, Hadi M Yassine und 3 weitere

Influenza and Other Respiratory Viruses · 2024

DOI: 10.1111/irv.13290 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Influenza and Other Respiratory Viruses, 2024. Verfasst von Salma Younes und 14 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Sciences Department, College of Health Sciences, Qatar University, Doha, Qatar. Hauptthemen laut MEDLINE: BNT162 Vaccine, Antibodies, Neutralizing, Antibodies, Viral, COVID-19. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: WHO, Qatar University, Qatar National Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Priming with ChAdOx1 followed by heterologous boosting is considered in several countries. Nevertheless, analyses comparing the immunogenicity of heterologous booster to homologous primary vaccination regimens and natural infection are lacking. In this study, we aimed to conduct a comparative assessment of the immunogenicity between homologous primary vaccination regimens and heterologous prime‐boost vaccination using BNT162b2 or mRNA‐1273.

Methods

We matched vaccinated naïve (VN) individuals ( n = 673) with partial vaccination ( n = 64), primary vaccination ( n = 590), and primary series plus mRNA vaccine heterologous booster ( n = 19) with unvaccinated naturally infected (NI) individuals with a documented primary SARS‐CoV‐2 infection ( n = 206). We measured the levels of neutralizing total antibodies (NTAbs), total antibodies (TAbs), anti‐S‐RBD IgG, and anti‐S1 IgA titers.

Results

Homologous primary vaccination with ChAdOx1 not only showed less potent NTAb, TAb, anti‐S‐RBD IgG, and anti‐S1 IgA immune responses compared to primary BNT162b2 or mRNA‐1273 vaccination regimens ( p < 0.05) but also showed ~3‐fold less anti‐S1 IgA response compared to infection‐induced immunity ( p < 0.001). Nevertheless, a heterologous booster led to an increase of ~12 times in the immune response when compared to two consecutive homologous ChAdOx1 immunizations. Furthermore, correlation analyses revealed that both anti‐S‐RBD IgG and anti‐S1 IgA significantly contributed to virus neutralization among NI individuals, particularly in symptomatic and pauci‐symptomatic individuals, whereas among VN individuals, anti‐S‐RBD IgG was the main contributor to virus neutralization.

Conclusion

The results emphasize the potential benefit of using heterologous mRNA boosters to increase antibody levels and neutralizing capacity particularly in patients who received primary vaccination with ChAdOx1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BNT162 VaccineAntibodies, NeutralizingAntibodies, ViralCOVID-19Immunization, SecondaryImmunoglobulin GSARS-CoV-22019-nCoV Vaccine mRNA-1273Immunoglobulin ACOVID-19 VaccinesHumansMaleFemaleAdultMiddle AgedYoung AdultFollow-Up StudiesVaccinationAgedImmunogenicity, VaccineAntibody FormationChAdOx1 nCoV-19Spike Glycoprotein, Coronavirus

Stichwörter der Autor:innen

COVID‐19antibodiesanti‐S1‐IgAanti‐S‐RBD IgGboosterimmune responseneutralizing antibodyvaccination

Substanzen

BNT162 VaccineAntibodies, NeutralizingAntibodies, ViralImmunoglobulin G2019-nCoV Vaccine mRNA-1273Immunoglobulin ACOVID-19 VaccinesChAdOx1 nCoV-19Spike Glycoprotein, Coronavirus

Autor:innen und Institutionen

  • Biomedical Sciences Department, College of Health Sciences, Qatar University, Doha, Qatar.
  • Biomedical Research Center, Qatar University, Doha, Qatar.
  • Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy.
  • Clinical Biochemistry, Tor Vergata University Hospital, Rome, Italy.
  • College of Dental Medicine, QU Health, Qatar University, Doha, Qatar.
  • Department of Basic Medical Sciences, College of Medicine, QU Health, Qatar University, Doha, Qatar.

ORCID-Profile: Laith J Abu-Raddad, Gheyath K Nasrallah

Förderung

  • WHO
  • Qatar University
  • Qatar National Research Fund
  • World Health Organization

Zitieren

APA

Younes, S., Nicolai, E., Pieri, M., Bernardini, S., Daas, H. I., Al-Sadeq, D. W., Younes, N., Shurrab, F. M., Nizamuddin, P. B., Humaira, F., Al-Dewik, N., Yassine, H. M., Abu-Raddad, L. J., Ismail, A., & Nasrallah, G. K. (2024). Follow‐Up and Comparative Assessment of SARS‐CoV‐2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA‐1273 Heterologous Booster Vaccination. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.13290

Vancouver

Younes S, Nicolai E, Pieri M, Bernardini S, Daas HI, Al-Sadeq DW, et al. Follow‐Up and Comparative Assessment of SARS‐CoV‐2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA‐1273 Heterologous Booster Vaccination. Influenza and Other Respiratory Viruses. 2024. doi:10.1111/irv.13290

BibTeX
@article{Younes2024,
  author = {Younes, Salma and Nicolai, Eleonora and Pieri, Massimo and Bernardini, Sergio and Daas, Hanin I and Al-Sadeq, Duaa W and Younes, Nadin and Shurrab, Farah M and Nizamuddin, Parveen B and Humaira, Fathima and Al-Dewik, Nader and Yassine, Hadi M and Abu-Raddad, Laith J and Ismail, Ahmed and Nasrallah, Gheyath K},
  title = {Follow‐Up and Comparative Assessment of SARS‐CoV‐2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA‐1273 Heterologous Booster Vaccination},
  journal = {Influenza and Other Respiratory Viruses},
  year = {2024},
  doi = {10.1111/irv.13290}
}
Kostenlos starten →